ClinicalTrials.gg
RecruitingNCT04798261Updated Nov 6, 2026

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

An observational study in Pulmonary Embolism, sponsored by Penumbra Inc.. Recruiting at 79 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Penumbra Inc. · Observational

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 4 months later.
Updated Nov 6, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Planned enrollment
17th of 68
1,500 · median 286
Started
2021
with 9 others
Observational
69 of 236
8 open now
Primary completion
2026-12
later than 13 of 42 live
Registered
169th of 236
by date

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 17th largest by planned enrollment of the 68 observational ones that give a count, is one of 10 that started in 2021, is one of 69 observational ones, reaches primary completion later than 13 of the 42 other live ones, and was the 169th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).

03

Conditions studied

  • Pulmonary Embolism

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute pulmonary embolism

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less
  2. RV/LV ratio ≥ 0.9 assessed by diagnostic computed tomographic angiography (CTA) or echocardiogram
  3. Frontline endovascular treatment with the Indigo Aspiration System per IFU
  4. Patient is ≥ 18 years of age
  5. obtained per Institutional Review Board/Ethics Committee requirements

Exclusion criteria

Exclusion Criteria:

  1. to systemic or therapeutic doses of anticoagulants (e.g. heparin)
  2. Stage IV () cancer, active lung cancer or previous history of surgery in the affected lung(s) or chest radiation
  3. Known serious, uncontrolled sensitivity to radiographic agents
  4. \< 180 days
  5. Patients on ECMO
  6. Pregnant patients
  7. Current participation in another drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
  8. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with acute pulmonary embolism

    Device: Indigo Aspiration System

Interventions

  • DeviceIndigo Aspiration System

    Indigo Aspiration System

06

What researchers measure

Primary outcomes

  1. Safety: Composite of major adverse events

    A composite of device-related death, major bleeding, device-related clinical deterioration, device-related pulmonary vascular injury and device-related cardiac injury

    Time frame: 48 hours

  2. Performance: Change in RV/LV Ratio

    Change in RV/LV Ratio (matched imaging pairs CTA or echocardiogram, as available)

    Time frame: 48 hours post-procedure

Secondary outcomes

  1. Quality of Life assessed via PEmb-QoL

    Self-assessment of PE related complaints and daily living limitations (including work and social)

    Time frame: 90 days post-procedure

  2. Quality of Life assessed via EQ-5D-5L

    Self-assessment of activities of daily living

    Time frame: 90 days post-procedure

  3. Functional outcome assessed NYHA

    Physician assessment of heart failure symptoms and activity level

    Time frame: 90 days post-procedure

  4. Functional outcome assessed via 6MWT

    Walking distance over a 6 minute period to assess functional capacity

    Time frame: 90 days post-procedure

  5. Perceived dyspnea assessed via Borg Scale

    Category rating scale to measure perceived dyspnea

    Time frame: 90 days post-procedure

  6. Incidence of device related SAE(s)

    Time frame: 365 days

  7. Any-cause mortality

    Time frame: Within 30 days

  8. Symptomatic PE recurrence

    Time frame: Within 30 days

07

Study locations

74 of 79 sites recruiting
08

References and documents

Publications

  • Moriarty JM, Schiro BJ, Dohad SY, Tamaddon H, Davis HC, Shavelle DM, Chrysant GS, Iliadis EA, Dexter DJ 2nd, Ciampi Dopazo JJ, Holden A, West FM, Keeling B, Sharp ASP, Weinberg I. Periprocedural Results and Right Ventricular Outcomes of Computer Assisted Vacuum Thrombectomy Treatment of Acute Pulmonary Embolism: Interim Analysis of 300 Patients From the STRIKE-PE Study. J Am Heart Assoc. 2025 Sep 2;14(17):e039975. doi: 10.1161/JAHA.124.039975. Epub 2025 Aug 29. PubMed 40878986 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.

Of 160 observational studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 105. This study's planned 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 15, 2021
StartActual
Jun 25, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
University Hospital of Wales is now Completed
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    University Hospital of Wales is now Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04798261
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Jun 25, 2021
Primary completion
Dec 2026 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Joanne Krasnoff
Contact
jkrasnoff@penumbrainc.com
650-455-4462
Aisha Pascua
Contact
apascua@penumbrainc.com
415-601-9561
John Moriarty, MD
principal investigator · University of California, Los Angeles
Aleksander Araszkiewicz, MD, PhD
principal investigator · Uniwersytecki Szpital Kliniczny w Poznaniu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion